Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography

Abstract

To elucidate further the potential of a Semliki Forest virus (SFV) vector in vivo for gene therapy, we constructed a vector, SFV-IL12, to transfer murine IL-12 genes into tumors. A single intratumoral injection of established B16 murine melanoma with SFV-IL12 resulted in a significant inhibition of tumor growth, while injection with SFV-LacZ had no effect. This antitumoral activity correlated with an increase of IFNγ production, MIG and IP-10 mRNA expression, both at the tumor site and at the periphery. In contrast, no increase in CTL- or NK cell-mediated cytotoxic response could be detected, ruling out the involvement of T and NK cell cytotoxicity. To determine how the transfer of IL-12 genes induced tumor regression, the antiangiogenicactivity of SFV-IL12 was investigated using Doppler ultrasonography (DUS). SFV-IL12 inhibited in situ neovascularization within the tumor, without affecting the resistance index of pre-existing intratumoral blood flows. In addition, histological analysis of SFV-IL12-treated tumors showed massive tumor necrosis induced by SFV-IL12 treatment. These data indicate that SFV-IL12 inhibits tumor growth through its antiangiogenic activity, demonstrated for the first time in vivo by DUS, and suggest that the SFV vector may be a novel valuable tool in tumor gene transfer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Colombo MP, Forni G . Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994 15: 48–51

    Article  CAS  PubMed  Google Scholar 

  2. Trinchieri G . Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes (review) Blood 1994 84: 4008–4027

    CAS  PubMed  Google Scholar 

  3. Chouaib S et al. Interleukin-12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors Proc Natl Acad Sci USA 1994 91: 12659–12663

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chua AO, Chizzonite R, Desai B . Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology with gp130 J Immunol 1994 153: 128–136

    CAS  PubMed  Google Scholar 

  5. Desai BB et al. The IL-12 receptor. II. Distribution and regulation of receptor expression J Immunol 1992 148: 3125–3132

    CAS  PubMed  Google Scholar 

  6. Manetti R et al. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces (Th1)-type specific immune responses and inhibits the development of IL-4 producing Th2 cells J Exp Med 1993 177: 1199–1204

    Article  CAS  PubMed  Google Scholar 

  7. Chan SH et al. Induction of IFN gamma production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers J Exp Med 1991 173: 869–879

    Article  CAS  PubMed  Google Scholar 

  8. Gately MK et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFNg in vivo Int Immunol 1994 6: 157–167

    Article  CAS  PubMed  Google Scholar 

  9. Brunda MJ et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors J Exp Med 1993 178: 1223–1230

    Article  CAS  PubMed  Google Scholar 

  10. Bramson JL et al. Direct intratumoral injection of an adenovirus-expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 Hum Gene Ther 1996 7: 1995–2002

    Article  CAS  PubMed  Google Scholar 

  11. Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc Natl Acad Sci USA 1996 93: 11302–11306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tahara H et al. Effective eradication of established murine tumors with interleukin-12 (IL-12) gene therapy using a polycistronic retroviral vector J Immunol 1995 154: 6466–6474

    CAS  PubMed  Google Scholar 

  13. Colombo MP et al. Amount of interleukin-12 available at the tumor site is critical for tumor regression Cancer Res 1996 56: 2531–2534

    CAS  PubMed  Google Scholar 

  14. Tsung K et al. IL-12 induces T helper 1-directed antitumor response J Immunol 1997 158: 3359–3365

    CAS  PubMed  Google Scholar 

  15. Liljeström P, Garoff H . A new generation of animal cell expression vectors based on the Semliki Forest virus replicon Bio/Technology 1991 9: 1356–1361

    Article  Google Scholar 

  16. Liljestrom P . Alphavirus expression systems Curr Opin Biotechnol 1994 5: 495–500

    Article  CAS  PubMed  Google Scholar 

  17. Mossman SP et al. Protection against lethal Simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine J Virol 1996 70: 1953–1960

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhou X et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine Vaccine 1994 12: 1510–1514

    Article  CAS  PubMed  Google Scholar 

  19. Zhang J et al. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells Gene Therapy 1997 4: 367–374

    Article  CAS  PubMed  Google Scholar 

  20. Folkman J . What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990 82: 4–6

    Article  CAS  PubMed  Google Scholar 

  21. O'Reilly MS et al. Angiostatin induces and sustains dormancy of human primary tumors in mice Nature Med 1996 2: 689–692

    Article  CAS  PubMed  Google Scholar 

  22. Holmgren L, O'Reilly MS, Folkman J . Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nature Med 1995 1: 149–153

    Article  CAS  PubMed  Google Scholar 

  23. Millauer B et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 1994 367: 576–579

    Article  CAS  PubMed  Google Scholar 

  24. Hori A et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor Cancer Res 1991 51: 6180–6184

    CAS  PubMed  Google Scholar 

  25. Rak JW, Croix BDS, Kerbel RS . Consequences of angiogenesis for tumor progression, metastasis and cancer therapy Anticancer Drugs 1995 6: 3–18

    Article  CAS  PubMed  Google Scholar 

  26. Voest EE et al. Inhibition of angiogenesis in vivo by interleukin-12 J Natl Cancer Inst 1995 87: 581–586

    Article  CAS  PubMed  Google Scholar 

  27. Bosari S et al. Microvessel quantitation and prognosis in invasive breast carcinoma Hum Pathol 1992 23: 755–761

    Article  CAS  PubMed  Google Scholar 

  28. Cosgrove DO et al. Breast diseases: color Doppler US in differential diagnosis Radiology 1993 189: 99–104

    Article  CAS  PubMed  Google Scholar 

  29. Lassau N et al. Value of high-frequency US for preoperative assessment of skin tumors Radiographics 1997 17: 1559–1565

    Article  CAS  PubMed  Google Scholar 

  30. Lamer S et al. Radiologic assessment of intranodal vascularity in head and neck squamous cell carcinoma. Correlation with histologic vascular density Invest Radiol 1996 31: 673–679

    Article  CAS  PubMed  Google Scholar 

  31. Karlan BY, Platt LD . The current status of ultrasound and color Doppler imaging in screening for ovarian cancer Gynecol Oncol 1994 55: S28–S33

    Article  CAS  PubMed  Google Scholar 

  32. Lee WJ et al. Breast cancer angiogenesis: a quantitative morphologic and Doppler imaging study Ann Surg Oncol 1995 2: 246–251

    Article  CAS  PubMed  Google Scholar 

  33. Lassau N et al. Value of high frequency ultrasound and color Doppler ulstrasound for preoperative assessment of melanoma. American Roetgenology Society. 98th Annual Scientific Meeting Am J Roentgenol 1998 170: 197 (Abstr. 412)

    Google Scholar 

  34. Watanabe M et al. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis Am J Pathol 1997 150: 1869–1880

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Kurjak A et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography J Ultrasound Med 1994 13: 295–301

    Article  CAS  PubMed  Google Scholar 

  36. Mu J et al. Administration of recombinant interleukin-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes Cancer Res 1995 55: 4404–4408

    CAS  PubMed  Google Scholar 

  37. Rakhmilevich AL et al. Gene gun-mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors Proc Natl Acad Sci USA 1996 93: 6291–6296

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yang Y et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses J Virol 1995 69: 2004–2015

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Zhou X et al. Generation of cytotoxic and humoral immune responses using non-replicative recombinant Semliki Forest virus Proc Natl Acad Sci USA 1995 92: 3009–3013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Nastala CL et al. Recombinant interleukin-12 administration induces tumor regression in association with interferon-gamma and nitric oxide production J Immunol 1994 153: 1697–1706

    CAS  PubMed  Google Scholar 

  41. Rodolfo M et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines J Immunol 1996 157: 5536–5542

    CAS  PubMed  Google Scholar 

  42. Barth RJJ et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes J Exp Med 1991 173: 647–658

    Article  CAS  PubMed  Google Scholar 

  43. Schijns VE et al. IFN-gamma receptor-deficient mice generate antiviral Th1-characteristic cytokine profiles but altered antibody responses J Immunol 1994 153: 2029–2037

    CAS  PubMed  Google Scholar 

  44. Boehm U et al. Cellular responses to interferon-gamma Annu Rev Immunol 1997 15: 749–795

    Article  CAS  PubMed  Google Scholar 

  45. Emoto M et al. Differences in the angiogenesis of benign and malignant ovarian tumors, demonstrated by analyses of color Doppler ultrasound, immunohistochemistry, and microvessel density Cancer 1997 80: 899–907

    Article  CAS  PubMed  Google Scholar 

  46. Teruya-Feldstein J et al. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein–Barr virus-positive lymphoproliferative disease Blood 1997 90: 4099–4105

    CAS  PubMed  Google Scholar 

  47. Fallarino F et al. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7–1-transfected tumor cells Int Immunol 1997 9: 1259–1269

    Article  CAS  PubMed  Google Scholar 

  48. Berglund P et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles Biotechnology (NY) 1993 11: 916–920

    CAS  Google Scholar 

  49. Asselin-Paturel C et al. Failure of TGFbeta1 and IL-12 to regulate human FasL and mTNF alloreactive cytotoxic pathways Tiss Antigen 1998 51: 242–249

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Asselin-Paturel, C., Lassau, N., Guinebretière, JM. et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 6, 606–615 (1999). https://doi.org/10.1038/sj.gt.3300841

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300841

Keywords

This article is cited by

Search

Quick links